Glatiramer acetate in multiple sclerosis: a review. (Q31118802)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Glatiramer acetate in multiple sclerosis: a review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Maria Trojano

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Maddalena Ruggieri

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Carlo Avolio

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

178-191

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00010.X

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00010.X

Degeneracy, as opposed to specificity, in immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00010.X

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00010.X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00010.X

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00010.X

The concept of specific immune treatment against autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00010.X

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment

21 January 2018

1 reference

12 December 2020

Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system.

1 reference

12 December 2020

Therapeutic strategies in multiple sclerosis. I. Immunotherapy

1 reference

12 December 2020

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

12 December 2020

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

1 reference

12 December 2020

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

12 December 2020

Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients

1 reference

12 December 2020

Apoptosis in multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

12 December 2020

Mechanisms of immunomodulation by glatiramer acetate

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

1 reference

12 December 2020

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

1 reference

12 December 2020

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

1 reference

12 December 2020

Glatiramer acetate in the treatment of multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate

1 reference

12 December 2020

Risk-benefit assessment of glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

The expression of pro- and anti-apoptosis Bcl-2 family proteins in lymphocytes from patients with multiple sclerosis

1 reference

12 December 2020

Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease

1 reference

12 December 2020

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

1 reference

12 December 2020

Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis

1 reference

12 December 2020

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

1 reference

12 December 2020

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

1 reference

12 December 2020

Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

1 reference

12 December 2020

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

1 reference

12 December 2020

Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate

1 reference

12 December 2020

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

1 reference

12 December 2020

Therapy with glatiramer acetate for multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

1 reference

12 December 2020

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

1 reference

12 December 2020

Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients

1 reference

12 December 2020

Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

1 reference

12 December 2020

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

1 reference

12 December 2020

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity

1 reference

12 December 2020

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

1 reference

12 December 2020

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.

1 reference

12 December 2020

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

1 reference

12 December 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

12 December 2020

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

1 reference

12 December 2020

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

1 reference

12 December 2020

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease

1 reference

12 December 2020

The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs

1 reference

12 December 2020

Copolymer 1: from basic research to clinical application

1 reference

12 December 2020

Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells

1 reference

12 December 2020

Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease

1 reference

12 December 2020

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

1 reference

12 December 2020

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study

1 reference

12 December 2020

Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis

1 reference

12 December 2020

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

1 reference

12 December 2020

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

1 reference

12 December 2020

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation

1 reference

12 December 2020

10.1111/J.1527-3458.2007.00010.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627671%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

PubMed publication ID

17627671

1 reference